Does Rallies show Form 4 insider transactions for TNDM?

Yes. Rallies tracks TNDM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TNDM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.

TNDM (Tandem Diabetes Care, Inc.) Stock Analysis - Insider Trades

Tandem Diabetes Care, Inc. (TNDM) is a publicly traded Healthcare sector company. As of May 21, 2026, TNDM trades at $14.85 with a market cap of $927.20M and a P/E ratio of -10.46. TNDM moved +8.51% today. Year to date, TNDM is -35.03%; over the trailing twelve months it is -36.05%. Its 52-week range spans $9.98 to $45.28. Analyst consensus is buy with an average price target of $30.76. Rallies surfaces TNDM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TNDM stock inside the company?

Recent TNDM insider activity includes Novara Mark David sold 187, Novara Mark David sold 2, Sheridan John F bought 10.00K, and Vosseller Leigh bought 13.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TNDM Key Metrics

Key financial metrics for TNDM
Metric	Value
Price	$14.85
Market Cap	$927.20M
P/E Ratio	-10.46
EPS	$-1.40
Dividend Yield	0.00%
52-Week High	$45.28
52-Week Low	$9.98
Volume	2.14K
Avg Volume	0
Revenue (TTM)	$1.03B
Net Income	$-94.55M
Gross Margin	54.93%

Recent TNDM Insider Trades

Novara Mark David sold 187 (~$4.31K) on Mar 17, 2026.
Novara Mark David sold 2 (~$45.62) on Mar 5, 2026.
Sheridan John F bought 10.00K (~$102.32K) on Aug 11, 2025.
Vosseller Leigh bought 13.72K (~$149.40K) on Aug 8, 2025.

Latest TNDM News

Tandem Diabetes Care Exceeds $1B Sales, Prepares Three New Pump Launches — Mar 3, 2026
Tandem Posts 58% Q4 Margin, Eyes Pharmacy Shift with $70–80M Headwind and “Toby” FDA Bid — Mar 2, 2026
Tandem Diabetes Upsizes $265M Convertible Notes at 37.5% Premium — Feb 25, 2026
Brown Capital Exits Tandem Diabetes Care Despite $290M Q4 Sales and 15% Growth — Feb 23, 2026
Tandem Diabetes Q4 Sales Rise 15% to $290.4M Drives 30% Stock Rally — Feb 20, 2026

TNDM Analyst Consensus

18 analysts cover TNDM: 0 strong buy, 9 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.76.

Common questions about TNDM

Who is trading TNDM stock inside the company?: Recent TNDM insider activity includes Novara Mark David sold 187, Novara Mark David sold 2, Sheridan John F bought 10.00K, and Vosseller Leigh bought 13.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TNDM?: Yes. Rallies tracks TNDM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TNDM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.